THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF CHLORPROPAMIDE

被引:2
|
作者
KALLIO, J
HUUPPONEN, R
PYYKKO, K
机构
[1] Departments of Pharmacology and Clinical Pharmacology, University of Turku
关键词
Chlorpropamide; Debrisoquine phenotype; Metabolism; Pharmacogenetics; Pharmacokinetics;
D O I
10.1007/BF02657068
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and urinary metabolite pattern of a single oral dose of chlorpropamide 250 mg have been studied in 6 extensive and 5 poor metabolizers of debrisoquine. Ammonium chloride was given orally to acidify the urine in order to make elimination of the parent drug dependent on metabolism alone. The concentration profile in serum and the pharmacokinetic parameters of the parent drug were similar in both groups. However, the ratio in urine of unchanged chlorpropamide to its hydroxylated metabolites was higher in poor than in extensive metabolizers. © 1990 Springer-Verlag.
引用
收藏
页码:93 / 95
页数:3
相关论文
共 50 条
  • [21] TIMOLOL METABOLISM AND DEBRISOQUINE OXIDATION PHENOTYPE - A POPULATION STUDY
    LENNARD, MS
    LEWIS, RV
    BRAUN, LA
    RAMSAY, LE
    JACKSON, PR
    TUCKER, GT
    WOODS, HF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (05) : P644 - P644
  • [22] EQUIVALENCE OF DEBRISOQUINE AND DEXTROMETHORPHAN TESTS FOR DETERMINING OXIDATION PHENOTYPE
    ROZENEK, S
    VINCENTVIRY, M
    MULLER, J
    GALTEAU, MM
    SIEST, G
    ANNALES DE BIOLOGIE CLINIQUE, 1988, 46 (07) : 534 - 534
  • [23] TIMOLOL AND ATENOLOL - RELATIONSHIPS BETWEEN OXIDATION PHENOTYPE, PHARMACOKINETICS AND PHARMACODYNAMICS
    LEWIS, RV
    LENNARD, MS
    JACKSON, PR
    TUCKER, GT
    RAMSAY, LE
    WOODS, HF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 19 (03) : 329 - 333
  • [24] DEBRISOQUINE OXIDATION PHENOTYPE AND NEUROLEPTIC-INDUCED DYSTONIC REACTIONS
    SPINA, E
    STURIALE, V
    VALVO, S
    ANCIONE, M
    DIROSA, AE
    MEDURI, M
    CAPUTI, AP
    ACTA PSYCHIATRICA SCANDINAVICA, 1992, 86 (05) : 364 - 366
  • [25] PREDICTING DEBRISOQUINE PHENOTYPE
    HEIM, M
    MEYER, UA
    LANCET, 1991, 337 (8737): : 363 - 363
  • [26] CHLORPROPAMIDE BIOAVAILABILITY AND PHARMACOKINETICS
    HUUPPONEN, R
    LAMMINTAUSTA, R
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1981, 19 (07) : 331 - 333
  • [27] PREDICTION OF DEBRISOQUINE PHENOTYPE
    WOLF, CR
    MOSS, JE
    MILES, JS
    GOUGH, AC
    SPURR, NK
    LANCET, 1991, 337 (8741): : 623 - 623
  • [28] Correlation between sparteine-debrisoquine oxidation phenotype and some parameters specifying severity of alcohol and tobacco dependence
    Beszlej, JA
    Chlebowska, I
    Kiejna, A
    PHARMACOPSYCHIATRY, 2002, 35 (05) : XI - XI
  • [29] DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE
    YUE, QY
    BERTILSSON, L
    DAHLPUUSTINEN, ML
    SAWE, J
    SJOQVIST, F
    JOHANSSON, I
    INGELMANSUNDBERG, M
    LANCET, 1989, 2 (8667): : 870 - 870
  • [30] LACK OF RELATIONSHIP BETWEEN QUINIDINE PHARMACOKINETICS AND THE SPARTEINE OXIDATION POLYMORPHISM
    NIELSEN, F
    ROSHOLM, JU
    BROSEN, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 48 (06) : 501 - 504